see Supplementary Table 1)
As we continue to add more medications that improve outcomes for patients with diabetic kidney disease, we will need to decide how we go about giving patients these medications, and we will need further trials to determine if there are benefits to being treated with as many kidney-protective medications as there are to offerSGLT2is, renin angiotensin system inhibitors, mineralocorticoid receptor antagonists, and now GLP-1 receptor agonists
Higher doses do not always produce better results
This means we dont just write a prescription and send you on your way
More Medication Can Distract From the Fundamentals No peptide stack replaces a sustainable calorie deficit, adequate protein, resistance training, sleep, and follow-up care
The effective exclusivity end date is determined by the last-expiring patent (or regulatory exclusivity) that a generic company cannot design around or successfully challenge